**6.1 Incidence**

Type 1 diabetes mellitus is also a rare a side effect in patients treated with immunotherapy. Type 1 DM has been observed in around 1% of patients treated with nivolumab and in 0.2% of patients treated with pembrolizumab. The median time of onset from starting immunotherapy is around 4.5 months.
